European advisory group thumbs up on Pfizer’s Humira biosimilar

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion backing approval of Pfizer’s (NYSE:PFE) Amsparity (adalimumab), a biosimilar to AbbVie’s (NYSE:ABBV) Humira.

Amsparity will be available in a 40 mg pre-filled syringe and pre-filled pen for adults and a 20 mg pre-filled syringe and 40 mg/0.8 mL vial for pediatric use.

A final decision from the European Commission usually takes ~60 days but has trended closer to 30 days recently.

https://seekingalpha.com/news/3526122-european-advisory-group-thumbs-up-on-pfizers-humira-biosimilar